Alnylam Pharmaceuticals
ALNY
#996
Rank
$18.95 B
Marketcap
$149.86
Share price
1.99%
Change (1 day)
-20.40%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2023 (TTM): $1.82 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $2.00 B. In 2022 the company made a revenue of $1.03 B an increase over the years 2021 revenue that were of $0.84 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2023

Annual revenue

Year Revenue Change
2023 (TTM) $1.82 B76.23%
2022 $1.03 B22.88%
2021 $0.84 B71.31%
2020 $0.49 B124.28%
2019 $0.21 B193.36%
2018 $74.9 M-16.69%
2017 $89.91 M90.66%
2016 $47.15 M14.75%
2015 $41.09 M-18.72%
2014 $50.56 M7.2%
2013 $47.16 M-29.31%
2012 $66.72 M-19.37%
2011 $82.75 M-17.28%
2010 $0.10 B-0.49%
2009 $0.10 B4.54%
2008 $96.16 M88.94%
2007 $50.89 M89%
2006 $26.93 M371.13%
2005 $5.71 M33.61%
2004 $4.27 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
$49.92 B 2,392.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$50.51 B 2,421.47%๐Ÿ‡ซ๐Ÿ‡ท France
$13.10 B 553.91%๐Ÿ‡บ๐Ÿ‡ธ USA
$1.40 B-29.95%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
$0.79 B-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
$16.00 B 698.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
$35.47 M-98.23%๐Ÿ‡บ๐Ÿ‡ธ USA